References
- Steinman L, Fox E, Hartung H-P, et al., Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8): 704–714.
- Mayo Clinic. Multiple sclerosis. 2022. cited 2022 Oct 25] Available 2022 Oct 25 from https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269
- O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:293–303.
- Svenningsson A, Frisell T, Burman J, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022;21(8):693–703.
- Montalban X, Hauser SL, Kapos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209.
- Bar-Or A, Grove RA, Austin DJ, et al., Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90(20): e1805–14.
- Fox E, Lovett-Racke AE, Gormley M, et al., A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3): 420–429.
- Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–557.
- Zhang Y, Yin H, Zhang D, et al. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: s prospective cohort study. J Neurol. 2022;268(9):4808–4816.
- ClinicalTrials.gov. An extension study of ublituximab in participants with relapsing multiple sclerosis. 2022. cited 2022 Sept 15]. Available from 2022 Sept 15: https://clinicaltrials.gov/ct2/show/NCT04130997?term=ublituximab&draw=2&rank=1
- Mukhtar H, Yasmeen U, Siddiqa S, et al. Outcomes of ublituximab compared to teriflunomide for relapsing multiple sclerosis: a meta-analysis. Mult Scler Relat Disord. 2022;65:104002.
- Multiple Sclerosis News Today. FDA decision on ublituximab for relapsing MS pushed to year’s end. 2022. cited 2022 Sept 20]. Available from 2022 Sept 20: https://multiplesclerosisnewstoday.com/news-posts/2022/06/01/fda-decision-ublituximab-relapsing-ms-pushed-back-years-end/
- Manchon E, Laplaud D, Vukusic S, et al. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: final results from the PRO-MSACTIVE study. Mult Scler Relat Disord. 2022;68:104109.